Printer Friendly

CYTOCARE REPORTS FIRST QUARTER RESULTS

 CYTOCARE REPORTS FIRST QUARTER RESULTS
 IRVINE, Calif., April 24 /PRNewswire/ -- Cytocare Inc.


(NASDAQ: CYTI) announced today earnings for the period ended March 31, 1992 of $388,596 or $.08 per share on revenues of $3,286,702. This compares with first quarter 1991 earnings of $501,534 or $.10 per share on revenues of $2,506,700. Results for the respective first quarters of 1992 and 1991 include procedure fees, equipment sales, maintenance fees, interest income and the realization of deferred revenue. Cytocare's research projects in urologic pharmaceuticals and devices are accelerating and an increasing portion of earnings will be plowed back into developing these markets this year.
 CYTOCARE INC.
 Condensed Comparative Operating Results
 March 31, 1992
 For the three months ended
 March 31,
 1992 1991
 Revenues $3,286,702(a) $2,506,700(b)
 Income before taxes $456,596(a) $536,534(b)
 Net income $388,596 $501,534
 Primary earnings per share:
 Net income $.08 $.10
 Fully diluted earnings per share:
 Net income $.08 $.10
 Number of shares used in the
 computation of earnings per share:
 Primary 5,141,439 4,837,727
 Fully diluted 5,141,439 4,943,028
 (a) Includes interest income of $171,018 and the recognition of $287,000 of deferred revenue.
 (b) Includes interest income of $179,747 and the recognition of $219,600 of deferred revenue.
 -0- 4/24/92
 /CONTACT: Jeannine Cormane of Cytocare, 714-587-0500/
 (CYTI) CO: Cytocare Inc. ST: California IN: MTC SU: ERN


EH-JL -- LA009 -- 2301 04/24/92 09:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 24, 1992
Words:254
Previous Article:ASTROTECH INTERNATIONAL CORPORATION DECLARES THIRD QUARTER DIVIDEND ON ITS $1.20 CUMULATIVE CONVERTIBLE PREFERRED DIVIDEND
Next Article:ALFRED BERKELEY JOINS COMSHARE'S BOARD OF DIRECTORS


Related Articles
CYTOCARE, INC. REPORTS YEAR-END RESULTS
CYTOCARE ANNOUNCES LITIGATION VICTORY
CYTOCARE FILES 510(k) SUBMISSION FOR LASER CATHETER FOR LASER SURGERY OF UROLOGICAL TISSUES
Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project.
Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project.
Health Robotics Expands CytoCare(TM) Global Presence With National Taiwan University Hospital and Pinnaclemed.
Health Robotics Expands CytoCare(TM) Global Presence With National Taiwan University Hospital and Pinnaclemed.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters